Xarelto matches standard in head-to-head blood clot trial

Citing long-term trial results, Germany's Bayer says that its top pipeline prospect, rivaroxaban (Xarelto), was just as effective as warfarin combined with Lovenox in preventing blood clots and did not raise the risk of bleeding. The data puts Bayer on a fast track toward an application to use the drug to prevent strokes as well as deep vein thrombosis, indications that could help build billions of dollars in annual revenue. "The results of this study confirm that the novel, convenient...

Bayer to open biotech Innovation Center in Pfizer’s old SF digs

To help in its hunt for new biotech collaborators active in hematology, oncology, cardiology, diagnostics and women's health, Bayer HealthCare is planning to open a U.S. Innovation Center and relocate 65 of its researchers to Pfizer's (NYSE: PFE) old offices in San Francisco. Bayer is taking half of Pfizer's old space near UC San Francisco's Mission Bay campus, according to the San Francisco Chronicle. And Nektar Therapeutics (NASDAQ: NKTR), which is relocating from San Carlos, is taking the...